<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708744</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2018-002</org_study_id>
    <nct_id>NCT03708744</nct_id>
  </id_info>
  <brief_title>A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers</brief_title>
  <official_title>A Randomized Open-label 4-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 at Two Different Application Locations for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, four-way crossover study. Each subject will
      receive each of the four study treatments once, followed by in-clinic monitoring and
      extensive blood sample collection for pharmacokinetic analysis.

      Dosing will occur approximately 48 hours apart, until completion of dosing in randomized
      order per the treatment sequence tables. Plasma samples from the dosing days will be sent to
      the analytical laboratory for analysis and tolerability for each of the dose levels will be
      summarized.

      After completion of the four dosing days, subjects will be assessed one final time and
      dismissed from the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized, four-way crossover study to compare the
      pharmacokinetics, safety and tolerability of:

      M207 3.8 mg administered to the upper arm to M207 3.8 mg administered to the thigh,
      particularly with respect to skin irritation (erythema, edema, bruising, bleeding):

      M207 3.8 mg worn for 30 minutes on the upper arm to M207 3.8 mg worn for 1 hour on the upper
      arm; and M207 3.8 mg to intranasal zolmitriptan 2.5 mg.

      Each subject will receive each of the four study treatments once, followed by in-clinic
      monitoring and extensive blood sample collection for pharmacokinetic analysis.

      M207 application sites will be observed for erythema, edema, bruising, and bleeding at
      various timepoints throughout the study.

      Dosing will occur approximately 48 hours apart, until completion of dosing in randomized
      order per the treatment sequence tables. Plasma samples from the dosing days will be sent to
      the analytical laboratory for analysis and tolerability for each of the dose levels will be
      summarized.

      After completion of the four dosing days, subjects will be assessed one final time and
      dismissed from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">November 20, 2018</completion_date>
  <primary_completion_date type="Actual">November 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label four-way crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose</time_frame>
    <description>maximum observed plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 hours</time_frame>
    <description>number of subjects that experienced at least one adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t(1/2)</measure>
    <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose</time_frame>
    <description>apparent half-life</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment D: Intranasal zolmitriptan 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: M207 3.8mg, 30 min, upper arm</intervention_name>
    <description>A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>A: Zolmitriptan patch, 3.8 mg, 30 min, upper arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: M207 3.8 mg, 30 min, thigh</intervention_name>
    <description>B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>B: Zolmitriptan patch 3.8 mg, 30 min, thigh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C: M207 3.8 mg, 1 hr, upper arm</intervention_name>
    <description>C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>C: Zolmitriptan patch, 3.8 mg, 1 hour, upper arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D:zolmitriptan nasal spray</intervention_name>
    <description>D: 2.5 mg/0.1 mL intranasal zolmitriptan</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>Zomig Nasal Spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women or men 18 to 50 years of age.

          2. Good general health with no clinically significant abnormalities as determined by
             medical history, physical examination, complete blood count (CBC), blood chemistry,
             urinalysis, and ECG.

          3. Negative urine drug and alcohol screens and negative serum pregnancy tests (for female
             subjects) at screening.

          4. Consent of female subjects to use a medically effective method of contraception
             throughout the entire study period and for 30 days after the subject completes the
             study. Medically effective methods of contraception that may be used by the subject
             include abstinence, use of diaphragm and spermicide, intrauterine device (IUD), condom
             and vaginal spermicide, hormonal contraceptives (subjects must be stable on hormonal
             contraceptives for at least the prior 3 months), surgical sterilization, and
             post-menopausal (â‰¥ 2 years of amenorrhea).

          5. Ability to read, understand, and provide written informed consent that they understand
             the purpose of the study and procedures required for the study before enrolling in the
             study, and willingness to comply with all study procedures and restrictions.

        Exclusion Criteria:

          1. Evidence of significant history of hepatic, reproductive, gastrointestinal, renal,
             bleeding, or hematological disorders including coagulation, pulmonary, neurological,
             respiratory, endocrine, or cardiovascular system abnormalities (especially
             hypertension, peripheral vascular disease, coronary artery disease, transient ischemic
             attacks, or cardiac rhythm abnormalities), psychiatric disorders, acute infection, or
             other conditions that would interfere with study participation or with the absorption,
             distribution, metabolism, or excretion of drugs.

          2. Presence of two or more risk factors for cardiovascular disease (family history of
             premature heart disease, hyperlipidemia, or hypertension)

          3. Any contraindication to zolmitriptan administration including:

               -  History of coronary artery disease or coronary vasospasm

               -  Symptomatic Wolf-Parkinson-White syndrome or other cardiac accessory conduction
                  pathway disorders

               -  History of stroke, transient ischemic attack, or hemiplegic or basilar migraine

               -  Peripheral Vascular Disease

               -  Ischemic bowel disease

               -  Uncontrolled hypertension

               -  Any history of hepatic impairment

          4. History of contact dermatitis or known dermatological disorders that would interfere
             with the study procedures or assessments

          5. Planned participation in activities which cause inflammation, irritation, sunburn,
             lesions, or tattoos at the intended application sites from 2 weeks prior to screening
             through their last day of study participation

          6. Use of warfarin within 1 month prior to the first dose or heparin within 1 week prior
             to study drug administration

          7. Use of prescription and over the counter medications other than the following:

               -  Hormone Replacement Therapy (HRT)

               -  Birth control pills, patches, injections, or implants (all hormonal
                  contraceptives) are allowed provided the dose has been stable for at least one
                  month prior to screening and may be continued throughout the study

               -  Antihistamines

               -  Intermittently used NSAIDS

               -  Acetaminophen if medically necessary (not more than 2 g/day)

               -  Exceptions may be allowed on a case by case basis

          8. Subjects who have a known allergy or sensitivity to zolmitriptan or its derivatives or
             formulations

          9. Known allergy or sensitivity to tapes, adhesives, or zolmitriptan

         10. Regular or recent intake of prescription drugs, particularly drugs with an influence
             on blood pressure.

         11. Use of any other investigational compound within one month of planned study drug
             dosing

         12. On-going drug or alcohol abuse, or history of either deemed to be clinically
             significant by the investigator

         13. Systolic BP (measured after remaining sitting for 5 minutes) greater than 140 mmHg and
             diastolic BP greater than 90 mmHg at screening

         14. History of nasal pathology (e.g., polyps) or abnormal nasal exam

         15. Body Mass Index (BMI) greater than 35 kg/m2

         16. If, in the opinion of the investigator, the subject is not suitable for the study

         17. Any positive urine drug screen result or alcohol breath test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Kellerman, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hill Top Research, Inc.</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <results_first_submitted>December 5, 2019</results_first_submitted>
  <results_first_submitted_qc>December 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 23, 2019</results_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Volunteer</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxazolidinones</mesh_term>
    <mesh_term>Zolmitriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03708744/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03708744/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>4-way crossover, each subject randomized to receive A, B, C, and D in one of four sequences.
A: M207 3.8 mg, two 1.9 mg patches, 30 min, upper arm B: M207 3.8 mg, two 1.9 mg patches, 30 min, thigh C: M207 3.8 mg, two 1.9 mg patches, 1 hr, upper arm D: Intranasal zolmitriptan 2.5 mg One subject randomized to CADB was given ABCD.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABCD</title>
          <description>A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application) B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application) C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application) D: Intranasal zolmitriptan 2.5 mg</description>
        </group>
        <group group_id="P2">
          <title>BDAC</title>
          <description>B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application) D: Intranasal zolmitriptan 2.5 mg A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application) C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)</description>
        </group>
        <group group_id="P3">
          <title>CADB</title>
          <description>C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application) A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application) D: Intranasal zolmitriptan 2.5 mg B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)</description>
        </group>
        <group group_id="P4">
          <title>DCBA</title>
          <description>D: Intranasal zolmitriptan 2.5 mg C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application) B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application) A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Each subject received each of the four treatments below in one of four treatment sequences.
A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application) B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application) C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application) D: Intranasal zolmitriptan 2.5 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.93" spread="3.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>maximum observed plasma concentration</description>
        <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
A: M207 3.8mg, 30 min, upper arm: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
B: M207 3.8 mg, 30 min, thigh: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
C: M207 3.8 mg, 1 hr, upper arm: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: Intranasal zolmitriptan 2.5 mg
D:zolmitriptan nasal spray: D: 2.5 mg/0.1 mL intranasal zolmitriptan</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum observed plasma concentration</description>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9180.9" spread="4066.1"/>
                    <measurement group_id="O2" value="5925.9" spread="2353.3"/>
                    <measurement group_id="O3" value="15224.3" spread="12972.9"/>
                    <measurement group_id="O4" value="3758.3" spread="1711.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>number of subjects that experienced at least one adverse event</description>
        <time_frame>24 hours</time_frame>
        <population>Subjects who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
A: M207 3.8mg, 30 min, upper arm: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
B: M207 3.8 mg, 30 min, thigh: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
C: M207 3.8 mg, 1 hr, upper arm: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: Intranasal zolmitriptan 2.5 mg
D:zolmitriptan nasal spray: D: 2.5 mg/0.1 mL intranasal zolmitriptan</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>number of subjects that experienced at least one adverse event</description>
          <population>Subjects who received treatment</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t(1/2)</title>
        <description>apparent half-life</description>
        <time_frame>pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
A: M207 3.8mg, 30 min, upper arm: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
B: M207 3.8 mg, 30 min, thigh: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
C: M207 3.8 mg, 1 hr, upper arm: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: Intranasal zolmitriptan 2.5 mg
D:zolmitriptan nasal spray: D: 2.5 mg/0.1 mL intranasal zolmitriptan</description>
          </group>
        </group_list>
        <measure>
          <title>t(1/2)</title>
          <description>apparent half-life</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.692" spread="0.486"/>
                    <measurement group_id="O2" value="2.975" spread="1.217"/>
                    <measurement group_id="O3" value="2.959" spread="0.998"/>
                    <measurement group_id="O4" value="4.545" spread="1.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
A: M207 3.8mg, 30 min, upper arm: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
B: M207 3.8 mg, 30 min, thigh: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
C: M207 3.8 mg, 1 hr, upper arm: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>Treatment D: Intranasal zolmitriptan 2.5 mg
D:zolmitriptan nasal spray: D: 2.5 mg/0.1 mL intranasal zolmitriptan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intranasal hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Don Kellerman, Sr. VP, Clinical Development and Medical Affairs</name_or_title>
      <organization>Zosano Pharma Corporation</organization>
      <phone>+1 (510) 745-4004</phone>
      <email>dkellerman@zosanopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

